Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- US FDA Accepts sNDA for Fycompa: Eisai
October 23, 2014
- Taisho Files NDA for Anti-Inflammatory Analgesic Patch for Osteoarthritis
October 23, 2014
- Obesity Drug Contrave Hits US Pharmacy Shelves: Takeda
October 23, 2014
- MTPC Downwardly Revises Half-Year, Full-Year Sales Forecasts
October 23, 2014
- Takeda Tops Physician Honoraria Payment List in FY2013
October 22, 2014
- Fujifilm to Ratchet Up Avigan Production for Ebola Treatment
October 21, 2014
- Shionogi Cuts Half-Year Net Profit Projection on Back Taxes
October 21, 2014
- Janssen Files Velcade in Japan for Mantle Cell Lymphoma
October 21, 2014
- Ribomic Ready to Out-License Aptamer-Based Drug RBM007
October 21, 2014
- GSK, Sumitomo Dainippon to Wind Up Paxil Copromotion at Year-End
October 21, 2014
- Nippon Boehringer Ingelheim Seeks Japan Approval for Nintedanib
October 21, 2014
- Alexion Submits NDA for Hypophosphatasia Treatment Asfotase Alfa
October 20, 2014
- Seikagaku Establishes Representative Office in US
October 20, 2014
- Astellas to End License Agreement with US Venture Company for AD Treatments
October 20, 2014
- AMO Japan Appoints Shoko Suzuki of Coca-Cola Japan as New President
October 20, 2014
- Takeda, euglena Strike Comprehensive Collaboration Deal for Euglena-Containing Product Development
October 20, 2014
- Bayer AG Aims to Achieve Japan Sales of 300 Billion Yen by 2017
October 17, 2014
- Bayer HealthCare Signs Two-Year Collaborative Search Activity Agreement with Kyoto Univ.
October 17, 2014
- FDA Gives Priority Review Status to Lenvatinib, Rufinamide: Eisai
October 17, 2014
- Pfizer Japan Voluntarily Recalls Torisel Due to Microparticles in Diluent
October 17, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…